A Brief History Of Semaglutide Research

Semaglutide (Somapacitan) is a next-generation GLP-1 (glucagon-like peptide-1) analog developed by Novo Nordisk of Denmark. Based on the basic structure of liraglutide, semaglutide is a long-acting formulation with enhanced efficacy in the treatment of type 2 diabetes. Novo Nordisk has completed six Phase IIIa studies of semaglutide injection and submitted a new drug application (NDA) for the once-weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. It has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). Semaglutide's once-daily oral formulation is currently in Phase III clinical trials.